ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1658

Interferon Related Soluble Mediator Concentrations Significantly Correlate with Disease Activity in SLE Patients with Active Interferon Pathways

Rufei Lu1, Cristina Arriens2, Teresa Aberle3, Stan Kamp3, Melissa E. Munroe3, Tim Gross1, Wade DeJager3, Susan Macwana3, Virginia C. Roberts3, Stephen Apel4, Hua Chen3, Eliza Chakravarty5, Katherine Thanou3, Joan T. Merrill6 and Judith A. James7, 1Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Oklahoma Medical research af, Edmond, OK, 6Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 7Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: cytokines and interferons, Gene Expression, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Systemic Lupus Erythematosus – Human Etiology and Pathogenesis Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose : Interferon (IFN) pathways are dysregulated in a subset of patients with systemic lupus erythematosus (SLE). IFN dysregulation likely contributes to SLE pathogenesis and influences the disease course. This study examined correlations between IFN transcriptional modular scores, biologically relevant soluble mediators, and SLE disease activity in patients with or without the IFN signature.

Methods : Adult SLE patients (n=49) meeting >/= 4 ACR classification criteria provided longitudinal samples at times of low (SLEDAI<6) and high (SLEDAI≥6) disease activity. Immune pathway activity was evaluated by modular transcriptional analysis of Illumina Beadchip Microarray gene expression data in 98 patient samples and 20 age, race and gender matched healthy controls. Plasma soluble mediators (n=23) and antinuclear antibodies (n=11) were assessed by multiplex-bead based assays and ELISAs. Non-parametric paired tests were used for intra-individual univariate analyses, conditional logistic regression for multivariate analyses.

Results : Within a given individual, IFN signatures remained active and did not change with disease activity. In patients with active IFN signatures (n=29), several soluble mediators were elevated during high compared to low disease activity. These included MIG (median 168 pg/mL vs. 100 pg/mL; p<0.01), IFNa (5.82 pg/mL vs. 3.69 pg/mL; p<0.01), MCP1 (240 pg/mL vs. 209 pg/mL; p<0.01), BLyS (1.88 ng/mL vs. 1.18 ng/mL, p<0.01), TNFRI (2.82 ng/mL vs. 1.98 ng/mL, p<0.05) and TNFRII (622 pg/mL vs. 552 pg/mL, p<0.01). Additionally, patients with active IFN signatures showed higher M4.11 plasma cell module scores and dsDNA concentrations during high vs. low disease activity (p<0.05). Periods of high disease activity in patients with active IFN signatures were best distinguished by M4.11 plasma cell module scores, BLyS, MIG and hemoglobin in multivariate logistic modeling (p<0.01).     

Conclusion: Although IFN activity correlates with disease severity in lupus populations, IFN module scores may not correlate significantly with intra-individual changes in disease activity. In contrast, plasma concentrations of IFN- and TNF-related soluble mediators significantly correlated with SLEDAI scores, suggesting that longitudinal monitoring of soluble mediators may be useful in individuals at increased risk of disease flares. 

 


Disclosure: R. Lu, None; C. Arriens, Exagen, 2; T. Aberle, None; S. Kamp, None; M. E. Munroe, None; T. Gross, None; W. DeJager, None; S. Macwana, None; V. C. Roberts, None; S. Apel, None; H. Chen, None; E. Chakravarty, None; K. Thanou, None; J. T. Merrill, Anthera Pharmaceuticals, Lilly, EMD Serono, GlaxoSmithKline and Biogen., 5; J. A. James, None.

To cite this abstract in AMA style:

Lu R, Arriens C, Aberle T, Kamp S, Munroe ME, Gross T, DeJager W, Macwana S, Roberts VC, Apel S, Chen H, Chakravarty E, Thanou K, Merrill JT, James JA. Interferon Related Soluble Mediator Concentrations Significantly Correlate with Disease Activity in SLE Patients with Active Interferon Pathways [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/interferon-related-soluble-mediator-concentrations-significantly-correlate-with-disease-activity-in-sle-patients-with-active-interferon-pathways/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interferon-related-soluble-mediator-concentrations-significantly-correlate-with-disease-activity-in-sle-patients-with-active-interferon-pathways/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology